667, L.P., Director at Kymera Therapeutics, Inc. (KYMR), bought 1 shares at $46.41 ($46) on 2024-08-20, disclosed to the SEC on 2024-08-22.
Open-market purchase of $46 KYMR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| ACAD | BUY | 2023-05-24 | $45.4M | — | Filing → |
| TCRX | BUY | 2022-05-12 | $4.8M | — | Filing → |
| IGMS | BUY | 2022-04-05 | $65.0M | — | Filing → |